Fluoxetine
- Generic Name
- Fluoxetine
- Brand Names
- Prozac, Sarafem, Symbyax
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18F3NO
- CAS Number
- 54910-89-3
- Unique Ingredient Identifier
- 01K63SUP8D
- Background
Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.
- Indication
Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present. Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar I Disorder, and treatment resistant depression. Fluoxetine is additionally indicated for the treatment of female patients with premenstrual dysphoric disorder (PMDD).
- Associated Conditions
- Alcohol Dependency, Anorexia Nervosa (AN), Bulimia Nervosa, Cataplexy, Depression, Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Myoclonus, Obesity, Obsessive Compulsive Disorder (OCD), Panic Disorder With Agoraphobia, Panic disorder without agoraphobia, Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD)
- Associated Therapies
- Maintenance therapy
Fluoxetine to Reduce Intubation and Death After COVID19 Infection
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- University of Toledo Health Science Campus
- Target Recruit Count
- 16
- Registration Number
- NCT04377308
- Locations
- 🇺🇸
University of Toledo, Toledo, Ohio, United States
The Activation on Prefrontal Cortex With Acupuncture and Moxibustion for Major Depressive Disorder: A Study of Functional Near Infrared Spectroscopy
- Conditions
- Depressive Disorder, Major
- Interventions
- Other: acupuncture and moxibustion
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Chengdu University of Traditional Chinese Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT04272476
- Locations
- 🇨🇳
Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China
Study on the Optimal Strategy of Chinese Patients With Bulimia Nervosa After Fluoxetine Treatment
- Conditions
- Fluoxetine
- Interventions
- Behavioral: dialectical behavior therapy (DBT)Behavioral: cognitive behavioral therapy (CBT)
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 550
- Registration Number
- NCT04154813
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China
Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Yale University
- Target Recruit Count
- 100
- Registration Number
- NCT04131829
- Locations
- 🇺🇸
Yale OCD Research Clinic - CMHC/CNRU, 34 Park ST, New Haven, Connecticut, United States
Poststroke Depression in Hemorrhagic Stroke
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 224
- Registration Number
- NCT03826875
- Locations
- 🇺🇸
Harborview Medical Center, Seattle, Washington, United States
Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2023-05-19
- Target Recruit Count
- 362
- Registration Number
- NCT03779789
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria Mater Domini, Università Magna Grecia, Catanzaro, Italy
🇮🇹Sapienza Università di Roma, Dipartimento di Neurologia e Psichiatria, Roma, Italy
🇮🇹Azienda Ospedaliera Universitaria Verona, Verona, Italy
Measuring Ambulation, Motor, and Behavioral Outcomes With Post-Stroke Fluoxetine in Tanzania
- Conditions
- Acute StrokeStroke, Ischemic
- Interventions
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT03728153
- Locations
- 🇹🇿
Muhimbili National Hospital, Dar es Salaam, Tanzania
Fluoxetine in Pulmonary Arterial Hypertension (PAH) Trial
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT03638908
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Allergan
- Target Recruit Count
- 501
- Registration Number
- NCT03569475
- Locations
- 🇺🇸
Manhattan Behavioral Medicine, PLLC, New York, New York, United States
🇺🇸AMR Conventions Limited, Naperville, Illinois, United States
🇺🇸AMR-Baber Research, Inc., Naperville, Illinois, United States
Bariatric Surgery and Pharmacokinetics of Fluoxetine
- Conditions
- Obesity, Morbid
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 12
- Registration Number
- NCT03476525
- Locations
- 🇳🇴
St. Olavs University Hospital, Trondheim, Norway
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.